Antengene Licenses ATG-106 to K2 Therapeutics in Potential $981 Million Deal
Antengene (HKG:6996) granted K2 Therapeutics rights outside Greater China to develop and commercialize ATG-106, a preclinical CDH6 x CD3 bispecific T-cell engager for solid tumors, according to a Monday Hong Kong bourse filing.The agreement entitles Antengene to about $20 million in upfront and near-term consideration, consisting of cash and a minority equity stake in a K2 subsidiary.The company is also eligible to receive up to $960.5 million in development, regulatory, and sales milestone payments, plus royalties on future net sales.Separately, K2 obtained an option to license an undisclosed preclinical bispecific T-cell engager candidate from Antengene.If exercised, the arrangement would provide Antengene with the upfront payment and near-term payments, up to $960.5 million in milestone payments, and royalties on future sales.
